AICAR: Endurance Claims, Doses and Trade-offs
Endurance · exercise-mimetic claims
AICAR attracts people hoping to make cardio feel easier, sustain hard efforts or lose fat. Its ‘exercise in a pill’ reputation began with a mouse treadmill result—not a demonstrated human fitness improvement.
Human research has not established a reliable performance benefit, fitness dose or safe cycle. WADA prohibits AICAR at all times.
2008 mouse treadmill experiment
44% farther on the treadmill
Relative distance · control set to 100
Dose and cycle claims: what was actually studied?
0.1 mg/kg/min
IV infusion in RED-CABG
For 7 hours around heart surgery, under hospital monitoring.
Not established
Human fitness dose or cycle
That surgical protocol cannot supply a daily injection or oral performance schedule.
The RED-CABG trial did not show its intended surgical benefit. Converting that infusion into a home-use amount would answer a different question from the one studied.
Reports of easier cardio can be difficult to interpret when training, injury recovery or other compounds change at the same time. Feeling more energetic also differs from improving a repeatable performance measure.
Two experiments, two different questions
| Compare | Mouse endurance study | Human RED-CABG trial |
|---|---|---|
| Who was studied? | Sedentary mice | People undergoing coronary bypass surgery |
| Question | Does treatment change treadmill endurance? | Does perioperative treatment reduce serious postoperative events? |
| Finding | Running endurance increased in the experimental model | The primary clinical outcome was not improved |
| What this cannot show | A human training replacement | Benefits of chronic use by healthy athletes |
The Mouse Study That Made It Famous
In the 2008 Cell paper, four weeks of AICAR increased treadmill running distance by 44% in sedentary mice. That figure describes a laboratory treadmill comparison. It is not a predicted improvement in a person’s race time, VO₂max or daily energy.
The experiment supports studying this metabolic pathway. It does not supply a validated human endurance dose, oral-product equivalence or a long-term safety profile. Original mouse experiment.
The Real Clinical History: Cardiac Surgery, Not Endurance
RED-CABG randomized 3,080 patients before stopping for futility: the planned analysis indicated little likelihood of showing the intended benefit. Acadesine did not improve the primary composite outcome of death, stroke or severe left-ventricular dysfunction through 28 days. This is useful human evidence, but specifically about an acute surgical treatment. JAMA trial abstract.
What AICAR Actually Does
Acadesine is AICA riboside, a nucleoside. Inside cells it can be converted into ZMP, the phosphorylated nucleotide that resembles AMP. This distinction explains why scientific sources sometimes use “AICAR” ambiguously for related chemical forms.
AMPK helps cells respond to energy demand. Influencing this system can change metabolic signaling, but switching on part of an exercise-related pathway does not reproduce every adaptation from training. Narkar et al..
Why WADA Banned It
The 2026 Prohibited List, S4.4.1, names AICAR among AMPK activators prohibited both in and out of competition. That status does not establish that a marketed product works or is safe. WADA list.
On “AICAR Peptide Benefits for Skin”
The endurance and surgical studies do not establish a cosmetic benefit. It is also inaccurate to claim that AMPK has no relevance to skin biology: lack of a demonstrated skin treatment is different from proving that a pathway cannot affect skin cells. Look for a controlled study of the actual formulation and skin outcome being advertised.
FAQ
Is AICAR a peptide? No. Acadesine is a nucleoside; its intracellular phosphorylated form is a nucleotide. Neither is an amino-acid chain.
Does clinical research make online AICAR products equivalent to a trial drug? No. The study’s formulation, route and quality controls matter.
Can a half-life curve show endurance benefits? No. A plot describes its stated exposure assumptions, not training adaptation or performance. Do not infer that a concentration peak is the best time to exercise.
What is the main risk question? The surgical trial cannot establish the safety of repeated, self-directed use by healthy people. Long-term treatment and combinations require their own evidence.
Primary sources
- Narkar et al., Cell 2008: animal endurance experiment.
- Newman et al., JAMA 2012: RED-CABG randomized trial.
- WADA 2026 Prohibited List: current sporting classification.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.